fda warning letters glp-1 compounders september 2025 news compounding The Food and Drug Administration (FDA) on Tuesday GLP-1 Compounding: When Innovation May
Description
In the STEP trials, which tested semaglutide 2.4 mg for weight management, nausea affected 43.9% of participants compared to 16.1% on placebo
Clinical Medicine: Therapeutics
Patients are now coming to their doctors with a new primary goal: weight loss
Yeah, I didnt even think of this because then Yeah, it is interesting
According to the American College of Gastroenterology, drugs that delay stomach emptying may cause gastroparesis
When President Trumps team of negotiators got Eli Lilly and Novo Nordisk to agree to a monthly $245 price in Medicare and Medicaid in November, that price was supposed to be for all GLP-1s, including those for obesity, which until then had not been covered by Medicare
